| Literature DB >> 33626356 |
Tadahito Yasuda1, Mayu Koiwa1, Atsuko Yonemura1, Keisuke Miyake1, Ryusho Kariya2, Sho Kubota3, Takako Yokomizo-Nakano3, Noriko Yasuda-Yoshihara4, Tomoyuki Uchihara1, Rumi Itoyama1, Luke Bu1, Lingfeng Fu1, Kota Arima1, Daisuke Izumi4, Shiro Iwagami4, Kojiro Eto4, Masaaki Iwatsuki4, Yoshifumi Baba4, Naoya Yoshida4, Hiroto Ohguchi5, Seiji Okada2, Keisuke Matsusaki6, Goro Sashida3, Akiko Takahashi7, Patrick Tan8, Hideo Baba9, Takatsugu Ishimoto10.
Abstract
In the tumor microenvironment, senescent non-malignant cells, including cancer-associated fibroblasts (CAFs), exhibit a secretory profile under stress conditions; this senescence-associated secretory phenotype (SASP) leads to cancer progression and chemoresistance. However, the role of senescent CAFs in metastatic lesions and the molecular mechanism of inflammation-related SASP induction are not well understood. We show that pro-inflammatory cytokine-driven EZH2 downregulation maintains the SASP by demethylating H3K27me3 marks in CAFs and enhances peritoneal tumor formation of gastric cancer (GC) through JAK/STAT3 signaling in a mouse model. A JAK/STAT3 inhibitor blocks the increase in GC cell viability induced by senescent CAFs and peritoneal tumor formation. Single-cell mass cytometry revealed that fibroblasts exist in the ascites of GC patients with peritoneal dissemination, and the fibroblast population shows p16 expression and SASP factors at high levels. These findings provide insights into the inflammation-related SASP maintenance by histone modification and the role of senescent CAFs in GC peritoneal dissemination.Entities:
Keywords: EZH2; H3K27me3 marks; JAK inhibitor; cancer-associated fibroblasts; gastric cancer; peritoneal dissemination; senescence-associated secretory phenotype
Mesh:
Substances:
Year: 2021 PMID: 33626356 DOI: 10.1016/j.celrep.2021.108779
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423